부산대학교 도서관

Consistent with the diagnosis-to-randomization analysis, patients with DS <=7 days were more likely to have adverse disease characteristics (e.g. double-hit lymphoma, bulky disease, high LDH, and fever) than those with longer DS (Table 1). Novel treatment regimens combining chemotherapy with targeted agents are being developed for diffuse large B-cell lymphoma (DLBCL). Our findings suggest that treatment delay due to biomarker testing does not affect outcome on this model, and should not preclude enrollment of patients into clinical trials. In step 2 of the 2-step analysis model, median SR time in patients with more aggressive disease (patients with DS <=7 days) was 7 days (range 1-26 days). [Extracted from the article]